Results v2
People everywhere are experiencing the pain relief benefits of CBDa, harnessing the power of plant-based medicine without the often harmful side effects of traditional pharma.
All I can say is WOW! I apply prior to, and as needed, post-ride. It’s very effective & works within an hour of application. And I get COMPLETE relief for about two hours.
—Gary, AZ
Muscle Rub
—Gary, AZ
Muscle Rub
From my experience with several different brands of CBD over the years, Planetarie’s product is far superior. I am def a fan!
— Steven, TX
Infusion
— Steven, TX
Infusion
He is running around with the kids when before he would not!!!! It seems to really help older dogs!!!!!
—Jennie, CO
K9 Infusion
—Jennie, CO
K9 Infusion
I found quite a bit of mobility back in my hands after taking the Softgels for 2 months.
— Greg, MO
Softgels
— Greg, MO
Softgels
I feel far more calm & focused when I add the Drink Additive to my morning coffee.
— Anastasia, CO
Drink Additive
— Anastasia, CO
Drink Additive
I can feel instant relief while using the Salve on my knee.
— Brenda, CO
Salve
— Brenda, CO
Salve
Discover why doctors and healthcare practitioners are increasingly recommending Planetarie’s water-extracted CBDa.
CBDa Muscle Rub is always in my bag with my cycling gear and I reach for it frequently to soothe the aches and pains that come from being a 60-year-old athlete.
Olympic Cyclist and Team USA
Cycling Coach
Chris Carmichael
Olympic Cyclist and Team USA
Cycling Coach
My patients and family find incredible healing with Planetarie, and I love that they use organic & functional ingredients to produce the most natural products.
Chiropractic Medicine
Sonja Kenyon, DC
Chiropractic Medicine
As a nutritionist and a product developer, I am very impressed with the stability and purity of Planetarie CBDa! I have used it in many custom, targeted health formulations for my clients; including one for a Doctor in Miami for use in management of clients struggling with intermittent stress, a group in South America planning a clinical trial, and several individual clients in Pennsylvania. We love the super clean process used to make this premium CBDa, and it always outperforms other CBDa products I’ve tried in formulations!
Registered Dietician
Crystal Webber, MS, RD
Registered Dietician
My patients are athletes with injuries, and they find incredible relief from Planetarie’s CBDa.
Chiropractic and Sports Medicine
Randall Pierce, DC
Chiropractic and Sports Medicine
CBDa is an important cannabinoid that I recommend to my patients on daily basis. I have been very pleased with quality and prices of Planetarie. Many of my patients reported that they had great results using Planetarie products.
Integrative Medicine & Professor GWU
Mikhail Kogan, MD
Integrative Medicine & Professor GWU
It's important to understand that not all CBD oils are created equal. The extraction process and purification process varies and can therefore affect the quality of the oil and the concentration of CBDa. Planetarie is unique in each of these areas. Their process is more natural with chemical free purification that produces a higher concentration of CBDa. Thanks to Planetarie and because of their quality products, there has been a profound change in my life.
Professor of Medicine, Pediatrics, and Surgery • Critical Care Section Chief, LSU Medical Center
L. Keith Scott, MD, MSc, FCCM
Professor of Medicine, Pediatrics, and Surgery • Critical Care Section Chief, LSU Medical Center
Ultimate Body Oil is a revolutionary approach to personal and intimate lubrication. The formula of using CBDa combined with high grade and high quality oils that are safe for internal tissues is an art. The presence of castor oil is anti-inflammatory as is CBDa. As a pelvic healthcare practitioner, I believe abdominal / digestive / pelvic inflammation is one of the core roots of all physiological dysfunction, disease, and challenging symptoms and illnesses. I firmly stand behind this product for use in my office as well as part of treatment planning for my clients. Whether suffering from pelvic pain, inflammation, pelvic / reproductive / digestive symptoms or simply looking to increase one's health and preventative healthcare routine with the added perk of pleasure, this product is an answer to a huge need and gap in the market of personal lubricants. Thank you to Planetarie for your innovation and creations.
Women’s Wellness Expert, MA, LPC, LMT
Alicia Patterson
Women’s Wellness Expert, MA, LPC, LMT
Cannabidiolic Acid
A review of current scientific literature regarding cannabis sativa derived cannabidiolic acid (CBDa). Namely, the physiological effects and possible pharmacological applications of this molecule.
White Paper Abstract
CBDa can be used in the future. The likely higher bioavailability seen in CBDa and other acidic cannabinoids as compared to their downstream neutral products means in many cases the target or anticipated effect can be achieved more efficiently with lower dosages. The higher bioavailability is due to traditional drug design parameters with CBDa having a pKa near the range of effective drug design and low clearance. CBDa acting on the endocannabinoid system (ECS) via endocannabinoid modulation is a mechanism that would be an important subject for human clinical trials. One of these trials could investigate the neuroprotective effects of CBDa via the inhibition of the major degrading enzyme of 2-AG, MAGL. 2-AG has been shown to be a main factor in lowering swelling in the brain post head injury.
If CBDa is effective at increasing 2-AG levels in the human brain it could be used as a preventative measure before high contact sports such as football or martial arts. In contrast, there is also the aspect of CBDa acting as an inhibitor of the major enzyme producing 2-AG, DAGL. If this effect is the more prominent effect seen in human clinical trials, it could be a target for diet and obesity drug design, as increased 2-AG levels are linked to abdominal obesity and metabolic issues. To figure out whether CBDa increases or decreases human 2-AG levels will be only discovered by more targeted studies though both options are exciting.
Another trial involving the ECS would involve the other major endocannabinoid AEA. CBDa in early studies has been found to inhibit cellular uptake of anandamide, limiting the inactivation and degradation of this molecule. Since increased levels of AEA have been shown to be act as an anxiolytic in rodent models, there is a need for CBDa to be studied for its ability to produce anti-anxiety effects in human clinical trials.
When looking at CBDa’s effects outside the ECS, one of the most important effects seen is the COX-2 inhibition. The selectivity of CBDa to favor the inhibition of COX-2 and not COX-1 means it can act as a potent anti-inflammatory while avoiding the side-effects seen with traditional NSAIDs. This has massive implications as a replacement for traditional anti-inflammatory drugs and should be a major target for human clinical trials. Additionally, CBDa is very potent for this pathway and can be used in very low amounts to achieve the desired effects.
Another pharmacological target outside the ECS is the anti-nausea effects exhibited by CBDa acting on the 5-HT(1A) receptor. The agonistic effect seen when CBDa binds the 5-HT(1A) receptor has been shown in rodent models to be a significant anti- nausea agent. Other cannabinoids such as CBD and d9-THC work in a similar fashion but CBD needed nearly 1000X the dosage to achieve the same effects and d9-THC is an intoxicating compound. The other problem with CBD for this purpose is the biphasic action of the molecule where too much will actually facilitate nausea. CBDa is evidenced to be a highly potent, non-intoxicating, anti-nausea target and does not suffer from unforeseen consequences due to biphasic dosing.
The final target for therapeutics covered in this paper is related to anti-hyperalgesia. This effect seems to be mediated by the agonist activity of CBDa at TrpV1 channels. TrpV1 is activated by heat, capsaicin, and other endogenous lipids. These channels are a major drug target and are thought to have a major role in chronic pain. Long term chronic pain is currently treated with often highly controlled and additive substances, finding a natural alternative such as CBDa would be highly desirable.
The team would like to acknowledge and thank all the sources used in this release. The scientists and doctors behind this work are the true pioneers of this industry, and we grateful for the information they have produced and shared.
If CBDa is effective at increasing 2-AG levels in the human brain it could be used as a preventative measure before high contact sports such as football or martial arts. In contrast, there is also the aspect of CBDa acting as an inhibitor of the major enzyme producing 2-AG, DAGL. If this effect is the more prominent effect seen in human clinical trials, it could be a target for diet and obesity drug design, as increased 2-AG levels are linked to abdominal obesity and metabolic issues. To figure out whether CBDa increases or decreases human 2-AG levels will be only discovered by more targeted studies though both options are exciting.
Another trial involving the ECS would involve the other major endocannabinoid AEA. CBDa in early studies has been found to inhibit cellular uptake of anandamide, limiting the inactivation and degradation of this molecule. Since increased levels of AEA have been shown to be act as an anxiolytic in rodent models, there is a need for CBDa to be studied for its ability to produce anti-anxiety effects in human clinical trials.
When looking at CBDa’s effects outside the ECS, one of the most important effects seen is the COX-2 inhibition. The selectivity of CBDa to favor the inhibition of COX-2 and not COX-1 means it can act as a potent anti-inflammatory while avoiding the side-effects seen with traditional NSAIDs. This has massive implications as a replacement for traditional anti-inflammatory drugs and should be a major target for human clinical trials. Additionally, CBDa is very potent for this pathway and can be used in very low amounts to achieve the desired effects.
Another pharmacological target outside the ECS is the anti-nausea effects exhibited by CBDa acting on the 5-HT(1A) receptor. The agonistic effect seen when CBDa binds the 5-HT(1A) receptor has been shown in rodent models to be a significant anti- nausea agent. Other cannabinoids such as CBD and d9-THC work in a similar fashion but CBD needed nearly 1000X the dosage to achieve the same effects and d9-THC is an intoxicating compound. The other problem with CBD for this purpose is the biphasic action of the molecule where too much will actually facilitate nausea. CBDa is evidenced to be a highly potent, non-intoxicating, anti-nausea target and does not suffer from unforeseen consequences due to biphasic dosing.
The final target for therapeutics covered in this paper is related to anti-hyperalgesia. This effect seems to be mediated by the agonist activity of CBDa at TrpV1 channels. TrpV1 is activated by heat, capsaicin, and other endogenous lipids. These channels are a major drug target and are thought to have a major role in chronic pain. Long term chronic pain is currently treated with often highly controlled and additive substances, finding a natural alternative such as CBDa would be highly desirable.
The team would like to acknowledge and thank all the sources used in this release. The scientists and doctors behind this work are the true pioneers of this industry, and we grateful for the information they have produced and shared.
Sign up today
Please provide your email and our White Paper & 2021 Addendum will be sent to you.
Not right now, thanks.